Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Croda Climbs After Deutsche Bank Recommends Buying: London Mover

Don't Miss Out —
Follow us on:

Aug. 23 (Bloomberg) -- Croda International Plc, the world’s second-largest maker of cosmetics ingredients, rose to the highest price in more than four months after Deutsche Bank AG recommended buying the shares.

The company’s earnings are supported by innovation, strong pricing power, acquisitions and exposure to emerging markets, Deutsche Bank analysts wrote in an Aug. 22 note, raising the recommendation on the stock to buy from hold.

The stock rose 4.3 percent to 2,677 pence, the highest since April 11, taking its advance to 13 percent this year and giving the company a market value of 3.6 billion pounds ($5.6 billion). It was the biggest gain on the FTSE 100 Index today. Deutsche Bank increased the price target for the Snaith, England-based company’s stock to 2,850 pence from 2,400 pence.

“Top-line growth has slowed over the past year,” Martin Dunwoodie, a Deutsche Bank analyst, said in the note. “We view this slowdown as cyclical rather than structural and expect sales growth to accelerate driven by a resumption of growth in crop care and personal care.”

Croda’s increasing focus on speciality products is driving an improvement in profit margins, Dunwoodie said. The chemical company bought a majority stake in Sichuan Sipo Chemical Co. of China for 38.2 million pounds this month to tap growing demand for car lubricant additives.

Sipo will become part of Croda’s Performance Technologies division, which has come to the fore amid competition and a slowdown in growth in the cosmetic-ingredients business that was the main growth driver.

Of analysts who monitor Croda and share their research with Bloomberg, eight recommend buying the stock, seven advocate holding and three advise selling.

To contact the reporter on this story: Rachel Savage in London at rsavage10@bloomberg.net

To contact the editor responsible for this story: Douglas Lytle at dlytle@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.